Physician profile
Cary Daniel
NPI 1417102658
$10,313.53
in general payments reported to CMS, 2019-2025
38 companies · $1,689 in 2025
The $1,689 reported for 2025 was more than what 92% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,388 · 2020: $860 · 2021: $1,795 · 2022: $1,275 · 2023: $1,826 · 2024: $1,480 · 2025: $1,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,905 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,905.36 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,689.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,616.26 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $1,139.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $958.54 | 2019-2025 | Airsupra, Lokelma, Farxiga |
| Amgen INC. | $704.05 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $543.19 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $488.03 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.70 | 2019-2022 | |
| Astellas Pharma US INC | $391.20 | 2023-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $347.18 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $245.76 | 2023-2025 | Austedo Xr, Austedo Xr |
| Pfizer INC. | $181.00 | 2019-2025 | |
| Exact Sciences Corporation | $141.54 | 2023-2025 | Cologuard Collection Kit |
| Sk Life Science, INC. | $125.00 | 2023 | Xcopri |
| Pharmacosmos Therapeutics INC. | $125.00 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $125.00 | 2023 | Dexcom G7 Gss (161) |
| Renalytix Ai, INC. | $123.01 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Novartis Pharmaceuticals Corporation | $109.81 | 2021-2023 | |
| Mannkind Corporation | $100.44 | 2022-2023 | Afrezza |
| Xeris Pharmaceuticals, INC. | $84.67 | 2023-2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $78.89 | 2019-2022 | |
| Horizon Therapeutics Plc | $64.12 | 2022 | |
| Glaxosmithkline, LLC. | $61.51 | 2019-2023 | Arexvy, Shingrix |
| Abbvie INC. | $57.66 | 2021 | |
| Medtronic, INC. | $51.27 | 2021-2022 | |
| Phadia US INC. | $37.15 | 2019-2024 | Immunocap |
| Esperion Therapeutics, INC. | $32.84 | 2021-2024 | Nexletol |
| Eisai INC. | $31.11 | 2025 | |
| Phathom Pharmaceuticals, INC. | $29.24 | 2024 | Voquezna |
| Ardelyx, INC. | $27.86 | 2024 | Ibsrela |
| Biohaven Pharmaceutical Holding Company Ltd. | $25.70 | 2022 | |
| Biogen, INC. | $24.50 | 2025 | Spinraza |
| Sanofi Pasteur INC. | $23.95 | 2021 | |
| Shield Therapeutics INC | $21.67 | 2023 | Accrufer |
| Arbor Pharmaceuticals, INC. | $17.00 | 2021 | |
| Hologic Sales and Service, LLC | $16.30 | 2024 | Aptima |
| Ultragenyx Pharmaceutical INC. | $15.38 | 2020 | |
| Qiagen, LLC | $13.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cary Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.